

# Total Syntheses of Conjugation-Ready Repeating Units of *Acinetobacter baumannii* AB5075 for Glycoconjugate Vaccine Development

Shuo Zhang<sup>[a, b]</sup> and Peter H. Seeberger<sup>\*[a, b]</sup>

**Abstract:** *Acinetobacter baumannii* is an opportunistic pathogen that causes serious nosocomial infections. One of the multidrug-resistant strains, AB5075, can result in bacteremia, pneumonia and wound infections associated with high morbidity and mortality. The structurally unique glycans on the surface of these bacteria are attractive targets for the development of glycoconjugate vaccines. Here, we report the

first total synthesis of the densely functionalized trisaccharide repeating unit of *A. baumannii* AB5075 as well as two analogues. The construction of 1,2-*cis* linkages between the rare sugars relies on a double-serial inversion strategy. The judicious selection of building blocks and reaction conditions allowed for stereoselective glycosylations, the installation of acetamido groups and the (S)-3-hydroxybutanoyl chain.

## Introduction

Infections caused by multidrug-resistant bacteria are increasing in frequency and result in high morbidity and mortality.<sup>[1–4]</sup> *Acinetobacter baumannii*, a Gram-negative coccobacillus, is one of the most prevalent causes of nosocomial infections<sup>[5,6]</sup> and is responsible for severe urinary tract infections, bacteremia and pneumonia.<sup>[7,8]</sup> The high adaptability of this bacterium has rendered multiple strains of *A. baumannii* resistant to almost all antimicrobials,<sup>[9–12]</sup> such that the World Health Organization lists this bacterium in the highest category of pathogens posing an imminent threat to human health. Vaccines against *A. baumannii* pathogens are urgently needed.

The outer membrane of *A. baumannii* AB5075 is surrounded by high molecular weight capsular polysaccharides (CPS)<sup>[13]</sup> that form a discrete layer on the bacterial surface, that assists in evasion of the host immune defenses and increases antibiotic tolerance.<sup>[14–16]</sup> CPS can trigger a specific immune response,<sup>[17,18]</sup> and renders the polysaccharides ideal targets for development of glycoconjugate vaccines.<sup>[19,20]</sup>

Identification of the immunogenic epitope is the key step for the development of novel vaccines.<sup>[21]</sup> Antigen candidates

synthesized based on CPS are important tools to elucidate the structures of anti-CPS antibodies.<sup>[19,22]</sup> Here, we report the first syntheses of a series of conjugation-ready oligosaccharides related to the CPS repeating unit of AB5075 as the basis for further immunological studies.

## Results and Discussion

The CPS of *Acinetobacter baumannii* AB5075 consists of two linear trisaccharide repeating units  $[-\rightarrow 3)-\beta\text{-D-ManpNAcA-(1}\rightarrow 4)-\beta\text{-D-ManpNAcA-(1}\rightarrow 3)-\alpha\text{-D-QuipNAc4NR-(1}\rightarrow ]$  where R indicates (S)-3-hydroxybutanoyl or acetyl in a ratio of approximately 2.5:1 (Figure 1A).<sup>[23]</sup> The repeating units bear *N*-acetyl groups on D-mannuronic acid and a (S)-3-hydroxybutanoyl group on D-bacillosamine. Three 1,2-*cis* linkages including two challenging  $\beta$ -mannosides and a terminal  $\alpha$ -glycosidic linkage, together with the presence of a (S)-3-hydroxybutanoyl group and dense *N*-acetyl groups make the trisaccharides very challenging targets to synthesize.

The retrosynthesis of target repeating unit **RU-1** reveals that trisaccharide **5** can be converted to the desired molecule via reduction, acetylation of azide groups and global deprotection (Figure 1B). The transformation of **4** to **5** involves the key reaction in this work: levulinoyl (Lev) groups are removed before double-serial inversion creates the two 1,2-*cis* mannosidic linkages. Trisaccharide skeleton **4** can be obtained by [1 + 1] and [1 + 2] glycosylations, the  $\beta$ -selectivity could be ascertained by the neighboring participation of 2-OLev groups.<sup>[24]</sup>


The total synthesis commenced with the preparation of the orthogonally protected rare sugar building blocks (Scheme 1). D-Bacillosamine derivative **1** was synthesized starting from the  $\alpha$ -selective glycosylation of selenoglycoside **6**<sup>[25]</sup> with amino-propyl linker **7** using NIS/TMSOTf as a promoter to give  $\alpha$ -linked glycoside **8** in 85% yield.<sup>[26]</sup> The linker is designed in anticipation of the conjugation to carrier protein or a microarray surface.<sup>[27]</sup> Removal of the 4,6-silyldene group employing

[a] S. Zhang, Prof. Dr. P. H. Seeberger  
Department of Biomolecular Systems  
Max Planck Institute of Colloids and Interfaces  
Am Mühlenberg 1, 14476 Potsdam (Germany)  
E-mail: Peter.Seeberger@mpikg.mpg.de

[b] S. Zhang, Prof. Dr. P. H. Seeberger  
Institute of Chemistry and Biochemistry  
Freie Universität Berlin  
Arnimallee 22, 14195 Berlin (Germany)

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/chem.202103234>

© 2021 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.




**Figure 1.** A) Structure of the *A. baumannii* AB5075 CPS repeating unit; B) Retrosynthetic analysis of target molecule RU-1.


HF-pyridine afforded diol **9**, then the C6 hydroxyl in **9** was tosylated using 4-toluenesulfonyl chloride to form **10** in 73% yield, followed by treatment with sodium iodide in refluxing acetone to obtain iodide **11**. Subsequently, reduction with tributyltin hydride and azobisisobutyronitrile (AIBN) at 75 °C gave **12** in 87% yield. The transformation of D-fucosamine derivative **12** to D-bacillosamine derivative **13** was carried out using nucleophilic displacement of the triflate. First, the C4 hydroxyl in **12** was triflated using triflic anhydride (Tf<sub>2</sub>O) and pyridine to form a 4-O-triflate intermediate. After a brief extraction, the triflate was treated with sodium azide in DMF to yield the desired **13**.<sup>[28]</sup> Removal of 2-naphthylmethyl (Nap) protecting group provided building block **1** in 89% yield.

For the synthesis of glucuronic acid building block **2**, the 4,6-benzylidene group of known thioglycoside **14**<sup>[29]</sup> was cleaved to form diol **15** (Scheme 1). Selective oxidation of the C6 hydroxyl group in **15** using 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) and bis(acetoxy)iodobenzene (BAIB) afforded the C6 carboxylic acid that was esterified with methyl iodide and K<sub>2</sub>CO<sub>3</sub> to give **16** in 62% yield over two steps.<sup>[30]</sup> Introduction of the fluorenylmethoxycarbonyl (Fmoc) protecting group on the C4 hydroxyl furnished desired building block **2** in good yield. As for the synthesis of building block **3**, oxidation and esterification of **17**<sup>[31]</sup> gave glucuronate **18** in 68% yield. Then, cleavage of the Nap ether in **18** and subsequent replacement by a Lev ester group furnished building block **3**.

With the building blocks in hand, the initial attempt to prepare trisaccharide started with the union of monosaccharides **1** with **2** in the presence of NIS/TfOH promoter, to form the desired disaccharide (Scheme 2). The triethylamine quenched also cleaved the Fmoc group to furnish β-linked disaccharide **20**




**Scheme 1.** Synthesis of building blocks **1**, **2** and **3**.



Scheme 2. Attempted assembly of trisaccharide RU-1.

in 67% yield while none of the  $\alpha$ -isomer was observed. The stereoselectivity is the result of the participating Lev ester in **2**.<sup>[24]</sup> Similarly, the [1 + 2] glycosylation of disaccharide **20** with building block **3** catalyzed by NIS and TfOH yielded the trisaccharide **4** with complete  $\beta$ -selectivity. The cleavage of Lev esters was followed by the conversion of the hydroxyl groups in **21** into triflates using  $\text{Tf}_2\text{O}$  and pyridine, concomitant replacement with tetrabutylammonium azide ( $\text{TBAN}_3$ ) in the axial positions gave the desired azide **5** in 72% yield. The four azide groups were then reduced with zinc followed by acetylation with acetic anhydride ( $\text{Ac}_2\text{O}$ ) in THF to obtain trisaccharide **22**. However, the attempted hydrolysis of the methyl ester with lithium hydroxide failed to produce the desired compound **23** as the very fragile glycosidic bond between two D-mannuronic acids was cleaved in the aqueous basic environment to generate mono- and disaccharide fragments.

Mindful of the lability of glycosidic bond that required us to avoid treating the trisaccharide with strong base, the C6 carboxylic acids in D-glucuronate building blocks were protected as benzyl instead of methyl esters. These benzyl ethers would be cleaved during final hydrogenolysis.<sup>[32]</sup> Similar to the synthesis of compound **2**, efficient oxidation and subsequent esterification with benzyl bromide and  $\text{NaHCO}_3$  led to the D-glucuronate **24** in 66% yield as a benzyl ester (Scheme 3A). Fmoc protection of the C4 hydroxyl group completed the synthesis of building block **25**. Selective cleavage of 4,6-benzylidene in thioglycoside **26**<sup>[33]</sup> formed **27** in 75% yield. Diol **27** was then converted to benzyl glucuronate **28** by regioselective oxidation of the C6-OH and esterification. Levulinoylation of the C2 hydroxyl group in **28** using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl) and DMAP produced building block **29**.

Scheme 3. A) Optimized D-glucuronate building blocks **25** and **29**; B) Assembly of trisaccharide repeating unit RU-1.

Following the initial route to **RU-1**, two sequential glycosylations using NIS/TfOH as promoter produced trisaccharide backbone **31** with exclusive  $\beta$ -selectivity (Scheme 3B). Cleavage of the Lev esters with hydrazine acetate freed two hydroxyl groups that were converted to 2',2'-bis triflates followed by replacement with azide nucleophiles in the axial position to generate azide **33** in good yield. The four azide groups were





Figure 2. Retrosynthetic analysis of target molecule **RU-2**.



Scheme 4. Synthesis of building blocks **34** and **35**.

reduced with zinc in the presence of acetic acid followed by acetylation with acetic anhydride in THF. Finally, the *N*-acetyl sugar was subjected to hydrogenolysis after extraction to furnish the repeating unit **RU-1** in 35% yield over two steps.

With **RU-1** in hand, the repeating unit of **AB5075** containing a (5)-3-hydroxybutanoyl chain served as the next target. The (5)-3-hydroxybutanoyl group must be installed prior to inversion due to the density of azides after inversion (Figure 2). Thus, an orthogonal azide group has to be included in building block **34** for subsequent reduction and coupling. A trichloroacetamido (TCA) group was chosen to mask the amino group of C2 in **34**.<sup>[34]</sup> Glycosylations of building blocks **34**, **25** and **35** will form trisaccharide backbone **36**, the exclusive azide in **36** will be reduced and (5)-3-hydroxybutanoyl chain can be introduced of this stage. If successful, the following inversion and global deprotection will produce the desired target molecule **RU-2**.

The synthesis of **34** commenced with the reduction of **11** with tributyltin hydride and AIBN at 85 °C, to reduce the C2-azide in **11** to the corresponding amino group and give **39** in 90% yield (Scheme 4). Installation of a TCA group to protect the amine was followed by inversion at the C4 position, *D*-bacillosamine derivative **41** was obtained in high yield. Removal of Nap ether with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) prepared **34** for glycosylation. For building block **35**, selective benzylidene opening of **42**<sup>[35]</sup> using  $\text{BH}_3\cdot\text{THF}$  and TMSOTf afforded diol **43** in 70% yield. Subsequent regioselective oxidation of the C6 hydroxyl group to the corresponding carboxylic acid was achieved efficiently using TEMPO/BAIB, followed by treatment with benzyl bromide and  $\text{NaHCO}_3$  to furnish **44** in 59% overall yield. The synthesis of **35** was completed after Lev protection of the C2 hydroxyl in 87% yield.

With all building blocks in hand, the coupling of **34** and **25** to form disaccharide **45** was explored. The conditions established for the synthesis of **RU-1**, a NIS/TfOH catalyzed glycosylation, afforded disaccharide **45** in low yield (Table 1, Entry 1). Higher temperatures (0 °C and 25 °C) or a NIS/TMSOTf promoter system (Table 1, Entry 2, 3 and 4) did not greatly increase the

**Table 1.** Glycosylation to synthesize disaccharide **45**.

Entry	Promoter	Temperature [°C]	Result
1	NIS/TfOH	−20 to 0	24% product formed, acceptor recovered
2	NIS/TfOH	0	25% product formed, acceptor recovered
3	NIS/TMSOTf	0	19% product formed, acceptor recovered
4	NIS/TfOH	0 to 25, overnight	33% product formed, acceptor recovered


yield. Possibly, introduction of the TCA group may be responsible for the decrease in the nucleophilicity of receptor **34**.<sup>[36]</sup>


In order to improve the efficiency of the glycosylation to obtain disaccharide **45**, the Fmoc protecting group in **25** was replaced with a strong electron-donating *tert*-butyldimethylsilyl ether (TBS) group. Glucuronate building block **46** was obtained after protection of the C4-OH as a TBS ether in **24** in 90% yield (Scheme 5A). The glycosylation of **34** using glycosylating agent **46** and NIS/TfOH as promoter at 0 °C was much more efficient and yielded 73%  $\beta$ -linked disaccharide **47** (Scheme 5B). Disaccharide acceptor **45** was furnished after TBS deprotection by TBAF and [1 + 2] glycosylation of **45** with **35** yielded trisaccharide **36** in  $\beta$  selectively. Chain elongation started from azide reduction of **36**. The Staudinger reaction failed for this trisaccharide,<sup>[37]</sup> while treatment with 1,3-propanedithiol was too mild to reduce the azide, instead, one chlorine of the TCA group was cleaved to give a 2-dichloroacetamido-4-azido product.<sup>[34,38]</sup> Finally, treatment of **36** with excess zinc and acetic acid at 40 °C in THF successfully converted the azide to the amine, subsequent coupling with freshly made (*S*)-3-*O*-benzylbutyryl chloride<sup>[39,40]</sup> gave **37** in 60% yield over two steps. The Lev esters were cleaved to get diol **48** with two hydroxyl groups

ready for inversion. However, triflation of the equatorial hydroxyl groups in **48** and its concomitant displacement with TBAN<sub>3</sub> failed to form the desired 2',2''-bis azide product **38**. The inversion succeeded only for the 2'-triflate, while the 2'-triflate was not substituted by azide but was hydrolyzed to give product **49** in 57% yield. The configuration and inversion site were determined with the assistance of HMBC and HSQC (Supporting Information). Increasing the temperature to 80 °C resulted in glycosidic bond cleavage between the two uronates.

Double-serial inversion conditions worked efficiently on **32** but not **48** mainly due to the installation of the (*S*)-3-hydroxybutanoyl chain, the most important difference between these two diols. Possibly, the steric hindrance of this chain interfered with the nucleophilic attack of azide on the 2'-triflate in the axial positions (Scheme 5B).<sup>[28,41]</sup>

To access the desired trisaccharide **38**, we turned to introduce the two axial azide groups by two separated inversions, that requires first inversion on disaccharide and second one after trisaccharide is assembled. Reduction of disaccharide **47** and subsequent coupling with (*S*)-3-*O*-benzylbutyryl chloride afforded **50** in 52% yield over two steps (Scheme 6). Lev ester was then removed and resulting alcohol

**Scheme 5.** A) Synthesis of building block **46**; B) Assembly of trisaccharide **49** and the attempted inversion.



**Scheme 6.** Synthesis of disaccharide **51** and separated inversions strategy attempt.

**51** was employed to triflation and inversion, unfortunately, none of desired product **52** was observed but rather starting material **51** was recovered.

Since the steric hindrance effect of (*S*)-3-hydroxybutanoyl chain was so strong that separated inversions strategy did not give access to desired product, we tried to temporarily protect the amine with Fmoc and proceed chain elongation after inversion stage (Scheme 7). Trisaccharide **36** was reduced efficiently to an amine by zinc and protected with Fmoc group to give **53** in 43% overall yield. Delevulinoylation of **53** using hydrazine acetate furnished diol **54** that was subjected to triflation by  $\text{F}_2\text{O}$  and pyridine. The subsequent inversion also failed to produce any azide product.


Attempts to synthesize the natural repeating unit **RU-2** did not meet with success, as the functionalization of amine within the *D*-bacillosamine derivative hinders the inversion process by disfavoring the substitution from the axial position. However, it is still a significant move to investigate the indispensability of 2'-acetamide and 2''-acetamide with the trisaccharide intermediates **48** and **49** we obtained.

Thus, to better understand the important role played of *N*-acetyl groups in antibody recognition, two analogues related to **RU-2** were synthesized (Scheme 8). **RU-A1** was obtained after the global deprotection of **48** in 52% yield. Synthesis of analogue **RU-A2** involved conversion of azide in **49** to the corresponding NHAc by treatment with zinc and  $\text{Ac}_2\text{O}$ , followed by the hydrogenolysis catalyzed over Pd/C to afford the second analogue **RU-A2** in 41% yield over two steps. Analogues **RU-A1**


and **RU-A2**, together with natural repeating unit **RU-1**, will be employed in glycan microarray to identify the key epitope that elicit specific immune responses against native AB5075 CPS.

## Conclusion

We report the first total synthesis of a densely functionalized aminoglycoside trisaccharide repeating unit of *A. baumannii* AB5075 as well as two analogues containing a challenging (*S*)-3-hydroxybutanoyl chain. Synthetic challenges associated with the complicated trisaccharide were overcome including  $\beta$ -mannoside synthesis, introduction of (*S*)-3-hydroxybutanoyl and the incorporation of labile glycosidic bonds. Orthogonally protected rare sugar building blocks provided efficient and stereoselective synthetic access to the trisaccharide,  $S_N2$  substitution of 2',2''-bis triflate allowed for the construction of multiple 1,2-*cis* linkages. Although the inversion on the trisaccharide containing the (*S*)-3-hydroxybutanoyl chain failed to deliver the desired 2',2''-bis azide product, the analogues based on **RU-2** provide the opportunity to investigate key epitopes that induce an antibody response against the native CPS of *A. baumannii*. Double-serial inversion in the context of complex oligosaccharides is a novel approach to the synthesis of complex aminoglycosides. Conjugation-ready sugars carrying an aminopropyl linker allows for easy access to glycan microarrays and in vivo immunological evaluation, *en route* to the



**Scheme 7.** Attempt of double-serial inversion with amine protection strategy.



Scheme 8. Synthesis of the analogues RU-A1 and RU-A2.

development of a synthetic glycoconjugate vaccine against *A. baumannii*.

## Acknowledgements

We gratefully acknowledge the Max-Planck Society for generous financial support. We sincerely thank Ms. Settels and Mr. Niemeyer for technical support. Open Access funding enabled and organized by Projekt DEAL.

## Conflict of Interest

The authors declare no conflict of interest.

**Keywords:** amides · carbohydrates · oligosaccharides · total synthesis · vaccines

- [1] A. P. Magiorakos, A. Srinivasan, R. B. Carey, Y. Carmeli, M. E. Falagas, C. G. Giske, S. Harbarth, J. F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D. L. Paterson, L. B. Rice, J. Stelling, M. J. Struelens, A. Vatopoulos, J. T. Weber, D. L. Monnet, *Clin. Microbiol. Infect.* **2012**, *18*, 268–281.
- [2] B. Vasey, D. A. Clifton, G. S. Collins, A. K. Denniston, L. Faes, B. F. Geerts, X. Liu, L. Morgan, P. Watkinson, P. McCulloch, *Nat. Med.* **2021**, *27*, 186–187.
- [3] C. Nathan, *Nat. Rev. Microbiol.* **2020**, *18*, 259–260.
- [4] S. Hernando-Amado, T. M. Coque, F. Baquero, J. L. Martínez, *Nat. Microbiol.* **2019**, *4*, 1432–1442.
- [5] L. Dijkshoorn, A. Nemeč, H. Seifert, *Nat. Rev. Microbiol.* **2007**, *5*, 939–951.
- [6] A. Y. Peleg, H. Seifert, D. L. Paterson, *Clin. Microbiol. Rev.* **2008**, *21*, 538–582.
- [7] F. C. Morris, C. Dexter, X. Kostoulas, M. I. Uddin, A. Y. Peleg, *Front. Microbiol.* **2019**, *10*, 1601.
- [8] R. Xie, X. D. Zhang, Q. Zhao, B. Peng, J. Zheng, *Emerg. Microbes Infect.* **2018**, *7*, 1–10.
- [9] A. C. Jacobs, M. G. Thompson, C. C. Black, *mBio* **2014**, *5*, 1–10.
- [10] C. Pimentel, C. Le, M. R. Tuttobene, T. Subils, J. Martinez, R. Sieira, K. M. Papp-Wallace, N. Keppetipola, R. A. Bonomo, L. A. Actis, M. E. Tolmasky, M. S. Ramirez, *Pathogenesis* **2021**, *10*, 1–13.
- [11] X. Wu, J. D. Chavez, D. K. Schweppe, C. Zheng, C. R. Weisbrod, J. K. Eng, A. Murali, S. A. Lee, E. Ramage, L. A. Gallagher, H. D. Kulasekara, M. E. Edrozo, C. N. Kamischke, M. J. Brittnacher, S. I. Miller, P. K. Singh, C. Manoil, J. E. Bruce, *Nat. Commun.* **2016**, *7*, 1–14.
- [12] D. Scribano, V. Marzano, S. L. Mortera, M. Sarshar, P. Vernocchi, C. Zagaglia, L. Putignani, A. T. Palamara, C. Ambrosi, *Int. J. Mol. Sci.* **2019**, *20*, 1–23.
- [13] J. K. Singh, F. G. Adams, M. H. Brown, *Front. Microbiol.* **2019**, *10*, 1–8.
- [14] J. A. Iwashkiw, A. Seper, B. S. Weber, N. E. Scott, E. Vinogradov, C. Stratilo, B. Reiz, S. J. Cordwell, R. Whittal, S. Schild, M. F. Feldman, *PLoS Pathog.* **2012**, *8*, e1002758.
- [15] S. J. Russo, D. M. Dietz, D. Dumitriu, J. H. Morrison, R. C. Malenka, E. J. Nestler, *Trends Neurosci.* **2010**, *33*, 267–276.
- [16] E. Geisinger, R. R. Isberg, *PLoS Pathog.* **2015**, *11*, e1004691.
- [17] M. T. Henke, E. M. Brown, C. D. Cassilly, H. Vlamakis, R. J. Xavier, J. Clardy, *Proc. Natl. Acad. Sci. USA* **2021**, *118*, 1–7.
- [18] X. Sun, G. Stefanetti, F. Berti, D. L. Kasper, *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 193–198.
- [19] P. H. Seeberger, *Chem. Rev.* **2021**, *121*, 3598–3626.
- [20] J. Enotarpi, M. Tontini, C. Balocchi, D. van der Es, L. Auberger, E. Balducci, F. Carboni, D. Proietti, D. Casini, D. V. Filippov, H. S. Overkleeft, G. A. van der Marel, C. Colombo, M. R. Romano, F. Berti, P. Costantino, J. D. C. Codeé, L. Lay, R. Adamo, *Nat. Commun.* **2020**, *11*, 1–9.
- [21] B. Schumann, K. Reppe, P. Kaplonek, A. Wahlbrink, C. Anish, M. Witznerath, C. L. Pereira, P. H. Seeberger, *ACS Cent. Sci.* **2018**, *4*, 357–361.
- [22] R. Rappuoli, *Sci. Transl. Med.* **2018**, *10*, 1–7.
- [23] S. N. Senchenkova, A. S. Shashkov, A. V. Popova, M. M. Shneider, N. P. Arbatsky, K. A. Miroshnikov, N. V. Volozhantsev, Y. A. Knirel, *Carbohydr. Res.* **2015**, *408*, 8–11.
- [24] S. Zhang, M. Sella, J. Sianturi, P. Priegue, D. Shen, P. H. Seeberger, *Angew. Chem. Int. Ed.* **2021**, *60*, 14679–14692; *Angew. Chem.* **2021**, *133*, 14800–14813.
- [25] D. van der Es, N. A. Groenia, D. Laverde, H. S. Overkleeft, J. Huebner, G. A. van der Marel, J. D. C. Codeé, *Bioorg. Med. Chem.* **2016**, *24*, 3893–3907.
- [26] B. Hagen, J. H. M. Van Dijk, Q. Zhang, H. S. Overkleeft, G. A. Van Der Marel, J. D. C. Codeé, *Org. Lett.* **2017**, *19*, 2514–2517.
- [27] F. Micoli, R. Adamo, P. Costantino, *Molecules* **2018**, *23*, 1–18.
- [28] S. R. Sanapala, S. S. Kulkarni, *J. Am. Chem. Soc.* **2016**, *138*, 4938–4947.
- [29] S. Arungundram, K. Al-Mafraji, J. Asong, F. E. Leach, I. J. Amster, A. Venot, J. E. Turnbull, G.-J. Boons, *J. Am. Chem. Soc.* **2009**, *131*, 17394–17405.
- [30] B. Schumann, R. Pragani, C. Anish, C. L. Pereira, P. H. Seeberger, *Chem. Sci.* **2014**, *5*, 1992–2002.
- [31] M. P. Lisboa, N. Khan, C. Martin, F. F. Xu, K. Reppe, A. Geissner, S. Govindan, M. Witznerath, C. L. Pereira, P. H. Seeberger, *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 11063–11068.



- [32] S. Visansirikul, J. P. Yasomane, P. Pornsuriyasak, M. N. Kamat, N. M. Podvalnyy, C. P. Gobble, M. Thompson, S. A. Kolodziej, A. V. Demchenko, *Org. Lett.* **2015**, *17*, 2382–2384.
- [33] L. Van Huy, C. Tanaka, T. Imai, S. Yamasaki, T. Miyamoto, *ACS Med. Chem. Lett.* **2019**, *10*, 44–49.
- [34] C. Qin, B. Schumann, X. Zou, C. L. Pereira, G. Tian, J. Hu, P. H. Seeberger, J. Yin, *J. Am. Chem. Soc.* **2018**, *140*, 3120–3127.
- [35] T. Angles d'Ortoli, G. Widmalm, *Tetrahedron* **2016**, *72*, 912–927.
- [36] D. Dhara, L. A. Mulard, *Chem. A Eur. J.* **2021**, *27*, 5694–5711.
- [37] S. Liu, K. J. Edgar, *Biomacromolecules* **2015**, *16*, 2556–2571.
- [38] J. Van Mechelen, J. Voorneveld, H. S. Overkleeft, D. V. Filippov, G. A. Van Der Marel, J. D. C. Codée, *Org. Biomol. Chem.* **2020**, *18*, 2834–2837.
- [39] M. Ohtawa, E. Shimizu, A. Saito, S. Sakamoto, A. Waki, A. Kondo, A. Yagi, R. Uchida, H. Tomoda, T. Nagamitsu, *Org. Lett.* **2019**, *21*, 5596–5599.
- [40] D. Y. Ma, D. X. Wang, J. Pan, Z. T. Huang, M. X. Wang, *J. Org. Chem.* **2008**, *73*, 4087–4091.
- [41] A. Behera, D. Rai, S. S. Kulkarni, *J. Am. Chem. Soc.* **2020**, *142*, 456–467.

---

Manuscript received: September 6, 2021

Accepted manuscript online: October 19, 2021

Version of record online: November 5, 2021